Takara Bio agreement with BioNTech Cell & Gene Therapies

Takara Bio has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies. Takara Bio will grant BioNTech a commercial license to use applicable patents relating to RetroNectin, and will provide BioNTech with supplies of RetroNectin.

The patented technologies licensed to BioNTech are based on Takara Bio’s proprietary RetroNectin method, which includes a technology enabling gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency. The RetroNectin method’s standard protocols are utilised for “Engineered T-cell Therapy”, which includes promising TCR and CAR gene therapies recently raising higher expectations.

BioNTech is allowed to use RetroNectin for production of its cell and gene therapy products, therapies in which a patient’s T cells are genetically engineered to express a CAR for the treatment of multiple solid tumours.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free